Chinook Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Chinook Therapeutics, a biopharmaceutical company focused on kidney diseases, will participate in two virtual investor conferences. The Piper Sandler 33rd Annual Virtual Healthcare Conference will have presentations available from November 22 to December 2, and a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference is scheduled for November 30 at 4:45 pm EST. Additionally, 1x1 meetings will take place through Evercore ISI and Piper Sandler on November 30, December 1, and December 2. Archived webcasts will be accessible for 90 days on the company’s website.

SEATTLE, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in the following upcoming virtual investor conferences:

• Piper Sandler 33^rd Annual Virtual Healthcare Conference – presentations will be available for registered attendees via the Piper Sandler conference site from November 22^nd to December 2^nd.
  
  
• 4^th Annual Evercore ISI HealthCONx Conference – fireside chat on Tuesday, November 30^th at 4:45 pm EST
  

Chinook will participate in 1x1 meetings through Evercore ISI on Tuesday, November 30^th and Wednesday, December 1^st and through Piper Sandler on Thursday, December 2^nd.

To access the live webcasts and subsequent archived recordings of these and other company presentations, please visit the Investors section of Chinook’s website. The archived webcasts will remain available for replay on Chinook’s website for 90 days.

About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.

Contact:
Noopur Liffick
Vice President, Investor Relations & Corporate Communications
investors@chinooktx.com
media@chinooktx.com

FAQ

What events will Chinook Therapeutics participate in for KDNY in November 2021?

Chinook Therapeutics will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 22 to December 2, and the Evercore ISI HealthCONx Conference with a fireside chat on November 30 at 4:45 pm EST.

How can I access the presentations for Chinook Therapeutics during the conferences?

Presentations will be available for registered attendees via the Piper Sandler conference site and can be accessed through Chinook’s website for 90 days post-event.

When will Chinook Therapeutics hold 1x1 meetings related to KDNY?

Chinook will hold 1x1 meetings through Evercore ISI on November 30 and December 1, and through Piper Sandler on December 2.